Selection of a lead candidate for the development of a novel anti-inflammatory therapeutic
Selection of a lead candidate for the development of a novel anti-inflammatory therapeutic
批准号:
10156864
负责人:
Aleah Fox Caulin
金额:
$29.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-15 至 2023-03-31
关键词:
AcuteAnti-Inflammatory AgentsBiologicalBiological AssayBiologyBiotechnologyBlood VesselsBlood specimenCaymansCell CountCessation of lifeChemotaxisChromatinClinical Trials DesignDNADataDepositionDevelopmentDiabetes MellitusDiseaseDrug KineticsEnsureEnzyme InhibitionEnzyme-Linked Immunosorbent AssayEventFluorescenceHalf-LifeHeartHeart DiseasesHigh Pressure Liquid ChromatographyHistonesHourHumanImmuneImmune responseIn VitroInfectionInflammationInflammatoryInjectionsLaboratoriesLeadLegal patentLicensingMeasuresMethionineMicrobeModalityModelingMolecularMorbidity - disease rateMusNatureNeonatalNervous System TraumaNorleucinePathogenesisPathway interactionsPatternPeptidesPeritonitisPhagocytosisPharmacodynamicsPhasePlasmaPositioning AttributePreventionPropertyProtein-arginine deiminaseProteinsRiversSepsisSmall Business Innovation Research GrantStrokeTherapeuticTherapeutic AgentsTissuesTreatment FactorUniversitiesUtahWorkantimicrobialbasececal ligation puncturechronic inflammatory diseasecommercializationcomparativecomparative efficacycoronavirus diseasedrug developmentexperienceexperimental studyextracellularfactor Ahuman diseaseimprovedin vitro activityin vivoinhibitor/antagonistintravenous injectionlead candidatelive cell imagingmortalitymouse modelneutrophilnovelnovel strategiesnovel therapeutic interventionpeptide Apeptide drugpharmacokinetics and pharmacodynamicspolymicrobial sepsispre-clinicalpreclinical studypreservationpreventscreeningstroke modelsuccesstherapeutic developmentvascular injury
中文摘要
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT
PEEL Therapeutics, Inc. (PEEL) is pioneering a novel approach to prevent morbidity and mortality
associated with inflammatory disease through the inhibition of neutrophil extracellular traps
(NETs). NETs are lattices of decondensed chromatin decorated with histones and antimicrobial
proteins extruded by polymorphonuclear leukocytes (PMNs) to trap and kill microbes. While
regulated NET formation contains infection, dysregulated NET formation leads to inflammatory
tissue damage and vascular injury. NETs have been implicated in human diseases characterized
by inflammation, including sepsis, stroke, diabetes, and heart disease. The ability of NET-
inhibitory factors (NIFs) to block PMN-dependent NET formation makes this newly described
class of endogenous peptides a promising therapeutic modality for diseases caused and/or
exacerbated by NET-dependent inflammatory events. In this Phase I SBIR, PEEL will quantify
and compare the biological activity and pharmacokinetics of two NIFs in vitro and in vivo. The
lead NIF peptide will move forward in the development of a novel anti-NET therapeutic. After
completing these SBIR Phase I tasks, PEEL Therapeutics will be in an excellent position to
advance its new and patented NIF-based therapeutic to further preclinical studies. These efforts
by PEEL Therapeutics hold the potential to disrupt and improve the treatment approach to both
acute and chronic inflammatory diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金